Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers

Purpose Fuzuloparib (AiRuiYi TM , formerly fluzoparib, SHR3162) is a new orally active poly adenosine diphosphate ribose polymerase (PARP) inhibitor. It has multiple pharmacological activities in breast, ovarian, and prostatic cancer. Fuzuloparib is mainly metabolized through the enzyme CYP3A4 may s...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer chemotherapy and pharmacology Vol. 89; no. 1; pp. 141 - 148
Main Authors:	Chen, Xue, Yang, Feng, Zhao, Jiao, Tang, Qi, Heng, Jianfu, Deng, Jun, Zhang, Jin, Chen, Yong, Li, Kunyan, Wang, Jing
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2022 Springer Nature B.V
Subjects:	Adenosine Adult Antifungal agents Aspartate transaminase Breast cancer Cancer Research Clinical Trial Report Cross-Over Studies Cytochrome P-450 CYP3A Inhibitors - adverse effects Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Fluconazole Fluconazole - adverse effects Fluconazole - pharmacokinetics Healthy Volunteers Humans Hyperlipidemia Male Medicine Medicine & Public Health Middle Aged Oncology Ovarian cancer Pharmacokinetics Pharmacology/Toxicology Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics Prostate cancer Ribose Transaminase Fluconazole CYP3A4 Drug–drug interaction (DDI) Fuzuloparib PARP inhibitor
ISSN:	0344-5704, 1432-0843, 1432-0843
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!